Abivax publishes its 2024 financial reports

Abivax SA, a Paris-based biotechnology company, filed its Universal Registration Document with the AMF and its Annual Report with the SEC on March 24, 2025. These filings include the 2024 annual financial report, as well as the management and corporate governance report, accompanied by the auditors' reports. Abivax, listed on Euronext Paris and Nasdaq, focuses on developing treatments that exploit the body's natural regulatory mechanisms for chronic inflammatory diseases. The documents are available on the Abivax, AMF, and SEC websites.